Linagliptin mot type 2-diabetes er trygt å bruke

Linagliptin approved for type 2 diabetes.

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes (T2DM). The novel compound linagliptin has important different pharmacokinetic (PK) properties, when compared with previously commercialized DPP-4 inhibitors, which may offer some advantages in clinical practice. Linagliptin has a unique PK/pharmacodynamic (PD) profile and is the first...

Linagliptin for elderly patients with type 2 diabetes.

306 www.thelancet.com Vol 383 January 25, 2014 The conclusion by Anthony Barnett and colleagues that in elderly patients with type 2 diabetes the safety profi le of linagliptin is similar to placebo, is misleading. As shown in table 3, drugrelated adverse events, serious adverse events, hospital admission, and adverse events leading to discontinuation of the drug were higher in the linagliptin ...

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment

Type 2 diabetes mellitus (T2DM) has a high prevalence and incidence around the world. The complex pathophysiology mechanism is among the barriers for diabetes treatment. Type 2 diabetes patients have dysfunction in incretin hormones (as glucagon-like peptide-1 or GLP-1, and glucose-dependent insulinotropic polypeptide or GIP). By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, it is possi...

Linagliptin use in older individuals with type 2 diabetes

Older people have the highest prevalence of type 2 diabetes mellitus (T2DM) of any age group and are thus frequent users of glucose-lowering agents. Because individuals 65 years or older are underrepresented in clinical studies, there is a lack of information regarding the efficacy and safety of available treatments in this population. Additionally, a high prevalence of comorbidities, polypharm...